Activated protein c analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats

Stroke

Volumn 44, Issue 12, 2013, Pages 3529-3536

  Wang, Yaoming ^a   Zhao, Zhen ^a   Chow, Nienwen ^b   Rajput, Padmesh S ^c   Griffin, John H ^d   Lyden, Patrick D ^c   Zlokovic, Berislav V ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ZZ Biotech Research Laboratory   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

Neuroprotectant; Protein C; Rats; Spontaneously hypertensive; Stroke

Indexed keywords

ALTEPLASE; HEMOGLOBIN; NEUROPROTECTIVE AGENT; RECOMBINANT 3K3A ACTIVATED PROTEIN C; UNCLASSIFIED DRUG;

ADHESIVE REMOVAL TEST; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CONTROLLED STUDY; FEMALE; FOOT FAULT TEST; FORELIMB; HEMISPHERE; HYPERTENSION; LOCOMOTION; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROLOGIC EXAMINATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SENSORIMOTOR FUNCTION; SPONTANEOUSLY HYPERTENSIVE RAT;

NEUROPROTECTANT; PROTEIN C; RATS, SPONTANEOUSLY HYPERTENSIVE; STROKE;

ANIMALS; BRAIN; BRAIN ISCHEMIA; DRUG INTERACTIONS; FEMALE; FIBRINOLYTIC AGENTS; MALE; MICE; NEUROPROTECTIVE AGENTS; PROTEIN C; RATS; RATS, INBRED SHR; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84889254676     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.003350     Document Type: Article

References (63)

1. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood. 2007;109:3161-3172.
2. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci. 2011;34:198-209.
3. Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9:338-342.
4. Liu D, Cheng T, Guo H, Fernández JA, Griffin JH, Song X, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2004;10:1379-1383.
5. Zlokovic BV, Zhang C, Liu D, Fernandez J, Griffin JH, Chopp M. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol. 2005;58:474-477.
6. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 2006;12:1278-1285.
7. Yesilirmak DC, Kumral A, Tugyan K, Cilaker S, Baskin H, Yilmaz O, et al. Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain Res. 2008;1210:56-62.
8. Thiyagarajan M, Fernández JA, Lane SM, Griffin JH, Zlokovic BV. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor. J Neurosci. 2008;28:12788-12797.
9. Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernández JA, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci. 2009;29:1119-1130.
10. Guo H, Wang Y, Singh I, Liu D, Fernández JA, Griffin JH, et al. Speciesdependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem. 2009;109:116-124.
11. Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, et al. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke. 2009;40:1864-1869.
12. Wang Y, Zhang Z, Chow N, Davis TP, Griffin JH, Chopp M, et al. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke. 2012;43:2444-2449.
13. Wang Y, Zhao Z, Chow N, Ali T, Griffin JH, Zlokovic BV. Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor. Brain Res. 2013;1507:97-104.
14. Guo H, Zhao Z, Yang Q, Wang M, Bell RD, Wang S, et al. An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci. 2013;33:6181-6190.
15. Petraglia AL, Marky AH, Walker C, Thiyagarajan M, Zlokovic BV. Activated protein C is neuroprotective and mediates new blood vessel formation and neurogenesis after controlled cortical impact. Neurosurgery. 2010;66:165-171, discussion 171.
16. Walker CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res. 2010;1347:125-131.
17. Taoka Y, Okajima K, Uchiba M, Murakami K, Harada N, Johno M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci. 1998;18:1393-1398.
18. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood. 2000;95:3781-3787.
19. Hirose K, Okajima K, Taoka Y, Uchiba M, Tagami H, Nakano K, et al. Activated protein C reduces the ischemia/reperfusion-induced spinal cord injury in rats by inhibiting neutrophil activation. Ann Surg. 2000;232:272-280.
20. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, et al. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119:3437-3449.
21. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, Ousman SS, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008;451:1076-1081.
22. Mosnier LO, Sinha RK, Burnier L, Bouwens EA, Griffin JH. Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood. 2012;120:5237-5246.
23. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
24. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178-3184.
25. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286-17293.
26. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernández JA, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors. Neuron. 2004;41:563-572.
27. Gorbacheva L, Davidova O, Sokolova E, Ishiwata S, Pinelis V, Strukova S, et al. Endothelial protein C receptor is expressed in rat cortical and hippocampal neurons and is necessary for protective effect of activated protein C at glutamate excitotoxicity. J Neurochem. 2009;111:967-975.
28. Gorbacheva L, Pinelis V, Ishiwata S, Strukova S, Reiser G. Activated protein C prevents glutamate-and thrombin-induced activation of nuclear factor-kappaB in cultured hippocampal neurons. Neuroscience. 2010;165:1138-1146.
29. Gale AJ, Tsavaler A, Griffin JH. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem. 2002;277:28836-28840.
30. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104:1740-1744.
31. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204:2439-2448.
32. Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cereb Blood Flow Metab. 2009;29:25-33.
33. Williams PD, Zlokovic BV, Griffin JH, Pryor KE, Davis TP. Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des. 2012;18:4215-4222.
34. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30:2752-2758.
35. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al; STAIR Group. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009;40:2244-2250.
36. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-928.
37. Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010;375:1667-1668.
38. Carpenter CR, Keim SM, Milne WK, Meurer WJ, Barsan WG; Best Evidence in Emergency Medicine Investigator Group. Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med. 2011;40:82-92.
39. Bouet V, Boulouard M, Toutain J, Divoux D, Bernaudin M, Schumann-Bard P, et al. The adhesive removal test: a sensitive method to assess sensorimotor deficits in mice. Nat Protoc. 2009;4:1560-1564.
40. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing JR. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
41. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011.
42. Chen B, Friedman B, Whitney MA, Winkle JA, Lei IF, Olson ES, et al. Thrombin activity associated with neuronal damage during acute focal ischemia. J Neurosci. 2012;32:7622-7631.
43. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476.
44. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab. 1990;10:290-293.
45. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, Marti HH, et al. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain. 2005;128(pt 1):52-63.
46. Gong Y, Hua Y, Keep RF, Hoff JT, Xi G. Intracerebral hemorrhage: effects of aging on brain edema and neurological deficits. Stroke. 2004;35:2571-2575.
47. Taguchi A, Soma T, Tanaka H, Kanda T, Nishimura H, Yoshikawa H, et al. Administration of CD34+ cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest. 2004;114:330-338.
48. Zhao BQ, Wang S, Kim HY, Storrie H, Rosen BR, Mooney DJ, et al. Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006;12:441-445.
49. Chen B, Friedman B, Cheng Q, Tsai P, Schim E, Kleinfeld D, et al. Severe blood-brain barrier disruption and surrounding tissue injury. Stroke. 2009;40:e666-e674.
50. Choudhri TF, Hoh BL, Solomon RA, Connolly ES Jr, Pinsky DJ. Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke. 1997;28:2296-2302.
51. Lapergue B, Dang BQ, Desilles JP, Ortiz-Munoz G, Delbosc S, Loyau S, et al. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke. Stroke. 2013;44:699-707.
52. Chen B, Cheng Q, Yang K, Lyden PD. Thrombin mediates severe neurovascular injury during ischemia. Stroke. 2010;41:2348-2352.
53. Jiang Q, Zhang RL, Zhang ZG, Ewing JR, Jiang P, Divine GW, et al. Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cereb Blood Flow Metab. 2000;20:21-27.
54. Nagai M, Re DB, Nagata T, Chalazonitis A, Jessell TM, Wichterle H, et al. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci. 2007;10:615-622.
55. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med. 1998;4:228-231.
56. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW. 1,026 experimental treatments in acute stroke. Ann Neurol. 2006;59:467-477.
57. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al; SAINT II Trial Investigators. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357:562-571.
58. Tymianski M. Can molecular and cellular neuroprotection be translated into therapies for patients?: yes, but not the way we tried it before. Stroke. 2010;41(10 suppl):S87-S90.
59. Fisher M, Albers GW, Donnan GA, Furlan AJ, Grotta JC, Kidwell CS, et al; Stroke Therapy Academic Industry Roundtable IV. Enhancing the development and approval of acute stroke therapies: Stroke Therapy Academic Industry roundtable. Stroke. 2005;36:1808-1813.
60. Saver JL, Johnston KC, Homer D, Wityk R, Koroshetz W, Truskowski LL, et al. Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials. The RANTTAS Investigators. Stroke. 1999;30:293-298.
61. Johnston KC, Wagner DP, Wang XQ, Newman GC, Thijs V, Sen S, et al; GAIN, Citicoline, and ASAP Investigators. Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke. 2007;38:1820-1825.
62. Hand PJ, Wardlaw JM, Rivers CS, Armitage PA, Bastin ME, Lindley RI, et al. MR diffusion-weighted imaging and outcome prediction after ischemic stroke. Neurology. 2006;66:1159-1163.
63. Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a Translational Medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28:217-219.